Biotechnology company Vaxart, Inc. (VXRT) announced Monday that the U.S. Food and Drug Administration (FDA) has completed its review of the Company's Investigational New Drug (IND) application for its Phase 1 clinical trial evaluating its oral COVID-19 vaccine candidate. The company also provided an update on its COVID-19 program.
from RTT - Biotech https://ift.tt/33uDrdo
via IFTTT
No comments:
Post a Comment